Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2016 · 10-Q
Revenue$2.06M$2.06M−2.9% vs Q2 2015 Net Income-$623.37K-$623.37KN/M vs Q2 2015 EPS Diluted-$0.04-$0.04N/M vs Q2 2015 Operating Income-$508,221N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$555,538N/M Margins · derivedOperating margin-24.7%+11.4 pt vs Q2 2015
Net margin-30.3%+11.6 pt vs Q2 2015
ended Sep 30, 2015 · filed Nov 13, 2015 · 44 d after period end